

Recent progress in the understanding, diagnosis, and treatment of
neuroendocrine tumors

Ca-A Cancer Journal for Clinicians

61, 113-132

DOI: [10.3322/caac.20097](https://doi.org/10.3322/caac.20097)

Citation Report

#	ARTICLE	IF	CITATIONS
1	mTOR/p70S6K in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 341-342.	2.5	4
2	Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model. Clinical Cancer Research, 2012, 18, 4621-4632.	3.2	34
3	Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead. Neuroendocrinology, 2012, 96, 261-271.	1.2	51
4	mTOR/p70S6K in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 341-341.	2.5	20
5	Neuroendocrine tumor of common hepatic duct. Indian Journal of Gastroenterology, 2012, 31, 144-146.	0.7	7
6	Pancreatic neuroendocrine tumor: Added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection. European Journal of Radiology, 2012, 81, e746-e749.	1.2	73
7	Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumours in a Danish NET Center. Scientific World Journal, The, 2012, 2012, 1-7.	0.8	6
8	Pancreatic neuroendocrine tumors: A comprehensive review. International Journal of Cancer, 2012, 131, 1013-1022.	2.3	30
9	Gastroenteropancreatic Neuroendocrine Tumors: Role of Imaging in Diagnosis and Management. Radiology, 2013, 266, 38-61.	3.6	156
10	Recent advances in multifunctional magnetic nanoparticles and applications to biomedical diagnosis and treatment. RSC Advances, 2013, 3, 10598.	1.7	87
11	Chemometric Evaluation of Urinary Steroid Hormone Levels as Potential Biomarkers of Neuroendocrine Tumors. Molecules, 2013, 18, 12857-12876.	1.7	5
12	Surgical Treatment and Survival in Patients with Liver Metastases from Neuroendocrine Tumors: A Meta-Analysis of Observational Studies. International Journal of Hepatology, 2013, 2013, 1-8.	0.4	28
13	Small bowel carcinoid: a rare cause of bowel obstruction. BMJ Case Reports, 2013, 2013, bcr2013200875-bcr2013200875.	0.2	2
14	KRAS and DAXX/ATRX Gene Mutations Are Correlated with the Clinicopathological Features, Advanced Diseases, and Poor Prognosis in Chinese Patients with Pancreatic Neuroendocrine Tumors. International Journal of Biological Sciences, 2014, 10, 957-965.	2.6	61
16	Genetic polymorphisms of inflammatory response gene TNF- α and its influence on sporadic pancreatic neuroendocrine tumors predisposition risk. Medical Oncology, 2014, 31, 241.	1.2	11
17	Senescence-related genes possibly responsible for poor liver regeneration after hepatectomy in elderly patients. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1102-1108.	1.4	28
18	Surgical Treatment and Clinical Outcome of Nonfunctional Pancreatic Neuroendocrine Tumors. Medicine (United States), 2014, 93, e94.	0.4	30
19	Evaluation of the World Health Organization 2010 Grading System in Surgical Outcome and Prognosis of Pancreatic Neuroendocrine Tumors. Pancreas, 2014, 43, 1003-1008.	0.5	63

#	ARTICLE	IF	CITATIONS
20	A Single Institution's Experience with Surgical Cytoreduction of Stage IV, Well-Differentiated, Small Bowel Neuroendocrine Tumors. <i>Journal of the American College of Surgeons</i> , 2014, 218, 837-844.	0.2	41
21	Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial. <i>European Journal of Cancer</i> , 2014, 50, 3107-3115.	1.3	82
22	New Insights into the Role of Chronic Inflammation and Cytokines in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2014, 99, 75-84.	1.2	28
23	Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems. <i>Medicine (United States)</i> , 2015, 94, e2156.	0.4	43
24	Surgical Indications, Timing, and Strategy in Non-colorectal Liver Metastases. , 0, , .		0
25	Magnetic nanomaterials with near-infrared pH-activatable fluorescence via iron-catalyzed AGET ATRP for tumor acidic microenvironment imaging. <i>Journal of Materials Chemistry B</i> , 2015, 3, 2786-2800.	2.9	33
26	Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. <i>Annals of Surgical Oncology</i> , 2015, 22, 2295-2301.	0.7	93
27	TNM Staging of Pancreatic Neuroendocrine Tumors. <i>Medicine (United States)</i> , 2015, 94, e660.	0.4	34
28	Pancreatic neuroendocrine tumors: correlation between histogram analysis of apparent diffusion coefficient maps and tumor grade. <i>Abdominal Imaging</i> , 2015, 40, 3122-3128.	2.0	49
29	Neuroendocrine tumor in the mandible: a case report with imaging and histopathologic findings. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 119, e41-e48.	0.2	2
30	Long term results of hepatic resection or orthotopic liver transplantation in patients with liver metastases from gastrointestinal neuroendocrine tumors. <i>Oncology Letters</i> , 2016, 12, 3563-3570.	0.8	4
31	Diabetes mellitus associated with pancreatic somatostatin tumor: A case report. <i>Journal of Clinical and Translational Endocrinology: Case Reports</i> , 2016, 2, 20-22.	0.4	2
32	Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1464-1470.	0.5	29
33	Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors: An Izmir Oncology Group Study. <i>Chemotherapy</i> , 2016, 61, 281-286.	0.8	46
34	Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study. <i>Scientific Reports</i> , 2016, 6, 36073.	1.6	35
35	Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors. <i>Medicine (United States)</i> , 2016, 95, e4213.	0.4	10
36	Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 284-288.	0.7	12
37	Outcomes of 101 Consecutive Surgical Resections of Gastroenteropancreatic Neuroendocrine Tumours (GEPNETs) at Tata Memorial Hospital: a Referral Bias for Nonfunctional Duodenopancreatic Tumours and the Need for Greater Awareness of GEPNETs as a Distinct Entity. <i>Indian Journal of Surgery</i> , 2017, 79, 226-233.	0.2	2

#	ARTICLE	IF	CITATIONS
38	Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution. <i>Journal of the American College of Surgeons</i> , 2017, 224, 434-447.	0.2	57
39	Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?. <i>Radiologia Medica</i> , 2017, 122, 319-326.	4.7	4
40	Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. <i>Clinical Therapeutics</i> , 2017, 39, 2158-2168.	1.1	38
41	Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. <i>Chinese Journal of Cancer</i> , 2017, 36, 51.	4.9	34
42	Prkar1a gene knockout in the pancreas leads to neuroendocrine tumorigenesis. <i>Endocrine-Related Cancer</i> , 2017, 24, 31-40.	1.6	26
43	Pancreatic neuroendocrine tumors. <i>Intractable and Rare Diseases Research</i> , 2017, 6, 21-28.	0.3	35
44	Imaging features of malignant abdominal neuroendocrine tumors with rare presentation. <i>Clinical Imaging</i> , 2018, 51, 59-64.	0.8	7
45	Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up. , 2018, , 203-222.		0
46	Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 261-268.	0.7	12
47	Imaging presentation of pancreatic neuroendocrine neoplasms. <i>Insights Into Imaging</i> , 2018, 9, 943-953.	1.6	18
48	Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. <i>Cancer Medicine</i> , 2018, 7, 2699-2709.	1.3	40
49	LncNEN885 inhibits epithelial-mesenchymal transition by partially regulation of Wnt/ β -catenin signalling in gastroenteropancreatic neuroendocrine neoplasms. <i>Cancer Science</i> , 2018, 109, 3139-3148.	1.7	17
50	Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2489-2496.	1.0	12
51	Economic analysis of inadequate symptom control in carcinoid syndrome in the United States. <i>Future Oncology</i> , 2018, 14, 2361-2370.	1.1	7
52	Utility of cytomorphology in distinguishing solid pseudopapillary neoplasm of pancreas from pancreatic neuroendocrine tumor with emphasis on nuclear folds and nuclear grooves. <i>Diagnostic Cytopathology</i> , 2019, 47, 531-540.	0.5	9
53	Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 69-75.	0.6	18
54	Multimodality Imaging of the Pancreatic Neuroendocrine Tumors. <i>Seminars in Ultrasound, CT and MRI</i> , 2019, 40, 469-482.	0.7	10
55	Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance. <i>Cancer Management and Research</i> , 2019, Volume 11, 1933-1944.	0.9	39

#	ARTICLE	IF	CITATIONS
56	Prognostic Validity of the American Joint Committee on Cancer Eighth Edition TNM Staging System for Surgically Treated and Well-Differentiated Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 613-621.	0.5	18
57	A novel and validated nomogram to predict overall survival for gastric neuroendocrine neoplasms. <i>Journal of Cancer</i> , 2019, 10, 5944-5954.	1.2	33
58	Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 507-511.	0.7	4
59	Comparative study of laparoscopic versus open radical gastrectomy in advanced gastric neuroendocrine carcinoma: Analysis from a high-volume institution. <i>Asian Journal of Surgery</i> , 2020, 43, 488-496.	0.2	3
60	Clinical Features and Long-Term Survival of Metastatic Hepatic Neuroendocrine Neoplasms Secondary to Gastroenteropancreatic Site: An Analysis by Applying the Grading Classification. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	0
61	Effects of tumor types on treatment strategy formulation and prognostic evaluation of gastric neuroendocrine tumors. <i>Future Oncology</i> , 2020, 16, 2197-2207.	1.1	5
62	Surgical management of insulinomas at the Azerbaijan Medical University: a retrospective study of 21 cases over a 10-year period. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1262-1269.	0.4	1
63	<p>Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6607-6614.	0.9	8
64	Label-Free Identification of Early Gastrointestinal Neuroendocrine Tumors via Biomedical Multiphoton Microscopy and Automatic Image Analysis. <i>IEEE Access</i> , 2020, 8, 105681-105689.	2.6	3
65	Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic. <i>Cancers</i> , 2020, 12, 3170.	1.7	13
66	Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency. <i>Pancreas</i> , 2020, 49, 408-412.	0.5	2
67	Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification. <i>Radiographics</i> , 2020, 40, 1240-1262.	1.4	64
68	Large cell neuroendocrine carcinoma in the unusual location of the descending colon. <i>Radiology Case Reports</i> , 2020, 15, 1841-1844.	0.2	1
69	Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients. <i>Frontiers in Oncology</i> , 2020, 10, 193.	1.3	7
70	SMALL INTESTINAL CARCINOID TUMOR-A CASE REPORT. , 2021, , 36-37.		0
71	Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE. <i>Endocrine Connections</i> , 2021, 10, 422-431.	0.8	5
72	Upper gastrointestinal bleeding as the initial manifestation of gastroenteropancreatic neuroendocrine tumors. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 618-619.	0.2	0
73	Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. <i>Neuroendocrinology</i> , 2022, 112, 298-310.	1.2	6

#	ARTICLE	IF	CITATIONS
74	Predicting the recurrence risk of pancreatic neuroendocrine neoplasms after radical resection using deep learning radiomics with preoperative computed tomography images. <i>Annals of Translational Medicine</i> , 2021, 9, 833-833.	0.7	14
75	Pancreatic neuroendocrine carcinoma in a pregnant woman: A case report and review of the literature. <i>World Journal of Clinical Cases</i> , 2021, 9, 4327-4335.	0.3	0
76	Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched caseâ€“control study. <i>Future Science OA</i> , 2021, 7, FSO684.	0.9	6
77	The overriding role of surgery and tumor grade for longâ€“term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A populationâ€“based cohort study. <i>Cancer Reports</i> , 2022, 5, e1462.	0.6	4
78	Management of Small Pancreatic Neuroendocrine Neoplasm. <i>Journal of Digestive Cancer Reports</i> , 2021, 9, 19-24.	0.0	0
79	Imaging of Pancreatic Neuroendocrine Neoplasms. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8895.	1.2	19
80	Pancreas Solid Tumors. <i>Surgical Clinics of North America</i> , 2020, 100, 565-580.	0.5	7
81	Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). <i>Medical Science Monitor</i> , 2018, 24, 8125-8140.	0.5	8
82	Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. <i>Oncotarget</i> , 2017, 8, 4935-4947.	0.8	25
83	A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition. <i>Oncotarget</i> , 2017, 8, 6929-6939.	0.8	35
84	A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. <i>Oncotarget</i> , 2017, 8, 71699-71708.	0.8	67
85	Association between ABO blood types and sporadic pancreatic neuroendocrine tumors in the Chinese Han population. <i>Oncotarget</i> , 2017, 8, 54799-54808.	0.8	3
86	Functional and non-functional pancreatic neuroendocrine tumours: ENETS or AJCC TNM staging system?. <i>Oncotarget</i> , 2017, 8, 82784-82795.	0.8	17
87	Current treatment status in pancreatic neuroendocrine neoplasms. <i>Chinese Clinical Oncology</i> , 2019, 8, 20-20.	0.4	4
88	The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologistâ€™s challenge. <i>Radiology and Oncology</i> , 2019, 53, 373-387.	0.6	36
89	Direct costs of carcinoid syndrome diarrhea among adults in the United States. <i>World Journal of Gastroenterology</i> , 2019, 25, 6857-6865.	1.4	7
90	Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies. <i>Gland Surgery</i> , 2014, 3, 243-51.	0.5	12
91	Diagnostic protocol for pancreatic neuroendocrine tumors (PNETs). <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 29-32.	0.1	4

#	ARTICLE	IF	CITATIONS
92	Zalecenia ogólne dotyczące postępowania w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską... Sieć Guzów Neuroendokrynnych). <i>Endokrynologia Polska</i> , 2014, 64, 418-443.	0.3	42
93	Somatostatin Analogues Do Not Prevent Carcinoid Crisis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6679-6683.	0.5	25
94	Late anastomotic perforation following surgery for gastric neuroendocrine tumor complicated by perforated duodenal ulcer: a case report. <i>Journal of Biomedical Research</i> , 2013, 27, 159-62.	0.7	0
95	Disseminated Intravascular Coagulation in a Patient with Metastatic Pancreatic Neuroendocrine Tumour: A Case Report and Review of the Literature. <i>Case Reports in Clinical Medicine</i> , 2014, 03, 549-553.	0.1	1
96	Clinicopathologic characters and outcomes of pancreatic neuroendocrine tumors: comparison of functioning versus non-functioning tumors. <i>Korean Journal of Clinical Oncology</i> , 2014, 10, 63-72.	0.1	0
97	ERUS and ERUS-FNA of Intramural and Extramural Masses of the Colorectum. <i>Essentials in Cytopathology Series</i> , 2015, , 111-149.	0.1	0
98	Role of Non-Functional Imaging in the Diagnosis of Abdominal Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 91-107.	0.0	0
99	The Pancreatic Endocrine Tumors - Experience of First Surgical Clinic Iasi. <i>Chirurgia (Romania)</i> , 2019, 114, 639.	0.2	0
100	Additional value of a dynamic contrast-enhanced study for detection of a small neuroendocrine tumor of the rectum on magnetic resonance imaging. <i>Radiologia Brasileira</i> , 2019, 52, 135-136.	0.3	0
101	Neuroendocrine Tumor: A Rare, Aggressive Tumor of the Gallbladder. <i>Cureus</i> , 2019, 11, e5571.	0.2	4
102	French patient-reported experience of diagnosis, management and burden of neuroendocrine tumors. <i>International Journal of Endocrine Oncology</i> , 2020, 7, .	0.4	1
103	Pancreatic Neuroendocrine Tumors: Experience of a Tertiary Care Center in Lebanon. <i>Annals of Cancer Research and Therapy</i> , 2020, 28, 9-15.	0.1	0
104	Response Assessment and Follow-Up by Imaging in Gastrointestinal Tumours. <i>Medical Radiology</i> , 2020, , 475-494.	0.0	0
105	Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea. <i>P and T</i> , 2019, 44, 424-427.	1.0	1
106	Divergent expression of DCLK1 in gastrointestinal neuroendocrine tumors and primary hepatic, gallbladder, and pancreatic neuroendocrine tumors. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 2249-2258.	0.5	0
107	Building multipurpose nano-toolkit by rationally decorating NIR-II fluorophore to meet the needs of tumor diagnosis and treatment. <i>Chinese Chemical Letters</i> , 2022, 33, 3478-3483.	4.8	9
108	Surgical Outcomes and Prognostic Factors of G3 Pancreatic Neuroendocrine Carcinomas: A Consecutive Analysis Based on Previous Study Results. <i>Journal of Clinical Medicine</i> , 2022, 11, 3176.	1.0	0
109	Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms. <i>World Journal of Gastroenterology</i> , 2022, 28, 3008-3026.	1.4	3

#	ARTICLE	IF	CITATIONS
110	Correlation of four-phase CT findings of rectal neuroendocrine neoplasms with different World Health Organization grades. <i>Abdominal Radiology</i> , 0, , .	1.0	0
111	Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists. <i>Tomography</i> , 2023, 9, 217-246.	0.8	3